UPT Perpustakaan Universitas Andalas
Repositori PerpustakaanUniversitas Andalas
 

HUBUNGAN TUMOR INFILTRATING LYMPHOCYTES (TIL) DENGAN STADIUM FIGO 2014 PADA KANKER EPITEL OVARIUM

dc.contributor.advisorAswiyanti, Asri
dc.contributor.authorPutri, Amanda
dc.date.accessioned2026-09-24T17:51:47Z
dc.date.issued2024-10-22
dc.descriptiondr. Aswiyanti Asri, M.Si.Med, Sp. PA (K)
dc.description.abstractKanker ovarium, sebagai kanker wanita kelima paling umum dan keganasan ginekologi paling mematikan di Indonesia dengan 9.673 kematian pada 2022, memiliki angka ketahanan hidup yang dipengaruhi oleh faktor prognostik seperti stadium dan Tumor Infiltrating Lymphocytes (TIL). Stadium kanker epitel ovarium mengikuti pedoman FIGO 2014, sementara TIL, yang terdiri dari limfosit seperti sel T, B, dan natural-killer, dapat ditemukan di jaringan tumor atau ruang peritumoral. Penelitian ini bertujuan untuk mengeksplorasi hubungan antara TIL dan stadium FIGO 2014 pada kanker epitel ovarium. Jenis penelitian ini adalah analitik komparatif kategorik tidak berpasangan dengan desain potong lintang (cross sectional). Populasi mencakup seluruh kasus kanker epitel ovarium yang didiagnosis di Laboratorium Patologi Anatomi RSUP Dr. M Djamil Padang pada 2021-2022, dengan 44 sampel yang diambil secara consecutive sampling. Instrumen yang digunakan adalah slaid HE dan data rekam medik. Hasil penelitian menunjukkan bahwa pada kanker epitel ovarium early stage, densitas TIL stroma rendah ditemukan pada 12 kasus (48%) dan densitas TIL stroma tinggi pada 13 kasus (68,4%). Pada advanced stage, densitas TIL rendah terdapat pada 13 kasus (52%) dan densitas TIL stroma tinggi pada 6 kasus (31,6%). Analisis data menunjukkan p-value = 0,295, sehingga kesimpulan penelitian ini adalah tidak terdapat hubungan signifikan antara Tumor Infiltrating Lymphocytes (TIL) dan Stadium FIGO 2014 pada kanker epitel ovarium.
dc.identifier.urihttps://ailib.my.id/handle/123456789/7984
dc.language.isoid
dc.publisherUniversitas Andalas
dc.subjectkanker epitel ovarium
dc.subjecttumor infiltrating lymphocytes
dc.subjectstadium FIGO 2014
dc.subject.classificationRB Pathology
dc.subject.classificationRG Gynecology and obstetrics
dc.titleHUBUNGAN TUMOR INFILTRATING LYMPHOCYTES (TIL) DENGAN STADIUM FIGO 2014 PADA KANKER EPITEL OVARIUM
dc.typeThesis
dcterms.dateSubmitted2024-11-29
dcterms.references1. Ma H, Tian T, Cui Z. Targeting ovarian cancer stem cells: a new way out. Stem Cell Res Ther. 2023;14(1):1–18. 2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4; 3. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2022: An overview. Int J Cancer. 2024;149(4):778–89. 4. Mitchell R. Traktus Genitalia Wanita. In: Buku Saku Dasar Patologis Penyakit. 7th ed. Jakarta, EGC; 2006. p. 621–6. 5. Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A. Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation—A nationwide case-control study. Int J Cancer. 2021;149(8):1544–52. 6. Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1). 7. James FR, Jiminez-Linan M, Alsop J, Mack M, Song H, Brenton JD, et al. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. BMC Cancer. 2017;17(1):1–7. 8. O’Shea AS. Clinical Staging of Ovarian Cancer. In 2022. p. 3–10. 9. Berek J, Hacker N, Hengst T. Gynecologic oncology. 6th ed. Elfrank J, editor. Philadelphia: Wolters Kluwer; 2015. 10. Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87. 11. Dinca AL, Birla RD, Dinca VG, Marica C, Panaitescu E, Constantinoiu S. Prognostic factors in advanced ovarian cancer - A clinical trial. Chir. 2020;115(1):50–62. 12. Khairallah AS, Genestie C, Auguste A, Leary A. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. Int J Cancer. 2018;143(1):8–15. 13. Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807–20. 14. Tomšová M, Melichar B, Sedláková I, Šteiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2008;108(2):415–20. 15. Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, et al. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia. 2018 Mar;20(3):280–8. 16. Vermeij R, de Bock GH, Leffers N, ten Hoor KA, Schulze U, Hollema H, et al. Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. J Immunother. 2011 Jul;34(6):516–23. 17. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clin Cancer Res. 2012 Jun 15;18(12):3281–92. 18. Salima S, Gandamihardja S, Harsono ALIB. Korelasi antara Ekspresi Tumor Infiltrating Lymphocytes CD4 dan CD8 dengan Kanker Ovarium Tipe Epitel Stadium Lanjut yang Bebas Penyakit dan Kekambuhan Penyakit dan Kekambuhan. Indones J Cancer. 2016;10(2):43–7. 19. Diana D, Kusmardi. Tumor-infiltrating lymphocytes dan Peranannya pada Karsinoma Payudara. Maj Patol Indones. 2020;29(1):30–40. 20. Hao J, Yu H, Zhang T, An R, Xue Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1–14. 21. Wang Q, Lou W, Di W, Wu X. Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int Immunopharmacol. 2017 Nov;52:7–14. 22. Valencia V, Asri A, Nizar RZ. Hubungan Ekspresi PD-L1 dengan Derajat Diferensiasi dan Densitas Til di Stroma pada Karsinoma Ovarium Serosum. Heal Med J. 2022;5(1):10–20. 23. Khatchapuridze K, Kordzaia S, Kekelidze N, Tsitsishvili Z, Mchedlishvili M K. Tumor infiltrating lymphocytes influence on prognosis and outcome of ovarian cancer. TCM&GMJ. 2020; 24. Kumar M, Eshwaraiah CB, Athira KP, Rudrappa SM. Correlation of Tumor-infiltrating Lymphocytes with Tumor Staging and Grading in Breast Carcinomas : A Retrospective Study. Int J Sci Res Dent Med Sci. 2023;5:16–20. 25. Rojas K, Prado-Vazquez G, Barcena C, Trilla-Fuertes L, Gamez-Pozo A, Zapater-Moros A, et al. Tumor-infiltrating Lymphocytes Expression in Stage IIIc/IV of High-grade Serous Ovarian Cancer: Variation with Neoadjuvant Chemotherapy and Prognostic Value. Oncogen. 2019 Mar 14;2(2). 26. Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia Volume 2. 24th ed. Singapore: Elsevier; 2019. 27. Giovannopoulou E, Karakasi MV, Kouroupi M, Ieronimaki AI, Papakonstantinou E, Giatromanolaki A, et al. Ovarian Morphometric and Histologic Characteristics and Correlation with Clinical Factors: A Cross-Sectional Study. J Pers Med. 2023 Jan 28;13(2):232. 28. Mescher AL. Junqueira’s Basic Histology: Text and Atlas. 17th ed. Boston: McGraw Hill/Medical; 2023. 29. Li L, Shi X, Shi Y, Wang Z. The Signaling Pathways Involved in Ovarian Follicle Development. Front Physiol. 2021 Sep 20;12. 30. Gershon E, Dekel N. Newly Identified Regulators of Ovarian Folliculogenesis and Ovulation. Int J Mol Sci. 2020 Jun 26;21(12):4565. 31. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021;155(S1):61–85. 32. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul 17;69(4):280–304. 33. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53. 34. Muhammad S, Fajriman F. Hubungan Nilai PCI Intraoperatif dengan Resektabilitas Kanker Ovarium di RSUP Dr. M. Djamil Padang. Indones J Obstet Gynecol Sci. 2023;6(3):365–73. 35. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99. 36. Park SU, Walsh L, Berkowitz KM. Mechanisms of ovarian aging. Reproduction. 2021 Aug 1;162(2):R19–33. 37. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32. 38. Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. Menopausal Rev. 2023;22(2):93–104. 39. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. J Turkish-German Gynecol Assoc. 2019 Mar 1;20(1):47–54. 40. Chesang JJ. Pathogenesis of Ovarian Cancer: Current Perspective. East Afr Med J. 2017;94(7):561–73. 41. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43. 42. Santosh SW, Freddy AJ, Winkins D. Oxidative Stress in the Pathogenesis of Ovarian Cancer. In: Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Singapore: Springer Nature Singapore; 2022. p. 3897–907. 43. Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022 Jan 14;14(2):416. 44. Adhikari L, Hassell LA. Ovary Tumor WHO Classifications [Internet]. PathologyOutlines.com website. [cited 2024 Jan 25]. Available from: https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html. 45. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020 Aug;158(2):316–22. 46. Zamwar UM, Anjankar AP. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. Cureus. 2022 Oct 21; 47. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021 Oct 20;155(S1):61–85. 48. Song Z, Zhou Y, Bai X, Zhang D. A Practical Nomogram to Predict Early Death in Advanced Epithelial Ovarian Cancer. Front Oncol. 2021 Mar 19;11. 49. Upadhyay A, Garg V, Mathur S, Singh Malik P, Bhatla N, Kumar S, et al. Early-Stage epithelial ovarian cancer: Predictors of survival. Gynecol Oncol Reports. 2022 Dec;44:101083. 50. Kehoe S. FIGO staging in ovarian carcinoma and histological subtypes. J Gynecol Oncol. 2020;31(4). 51. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020. JNCCN J Natl Compr Cancer Netw. 2021;19(2):191–226. 52. World Health Organization. Global Cancer Observatory [Internet]. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf 53. Zhang D, He W, Wu C, Tan Y, He Y, Xu B, et al. Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Front Immunol. 2019 Jan 29;10. 54. Fanale D, Dimino A, Pedone E, Brando C, Corsini LR, Filorizzo C, et al. Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. Cancers (Basel). 2022 Sep 6;14(18):4344. 55. Macchetti AH, Marana HRC, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S. TUMOR-INFILTRATING CD4+ T LYMPHOCYTES IN EARLY BREAST CANCER REFLECT LYMPH NODE INVOLVEMENT. Clinics. 2006;61(3):203–8. 56. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Nov 7;19(11):1423–37. 57. Machuca-Aguado J, Conde-Martín AF, Alvarez-Muñoz A, Rodríguez-Zarco E, Polo-Velasco A, Rueda-Ramos A, et al. Machine Learning Quantification of Intraepithelial Tumor-Infiltrating Lymphocytes as a Significant Prognostic Factor in High-Grade Serous Ovarian Carcinomas. Int J Mol Sci. 2023 Nov 7;24(22):16060. 58. Hwang C, Lee S, Lee J, Kim K, Suh D, Kwon B, et al. Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. Oncol Lett. 2019 Mar 1; 59. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinom. Adv Anat Pathol. 2017 Nov;24(6):311–35. 60. Wang Y, Zhu T, Shi Q, Zhu G, Zhu S, Hou F. Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy. J Immunother Cancer. 2024 Jan 19;12(1):e008026. 61. Zhao W, Zhai W. IL-36 α inhibits the progression of Colorectal Cancer via inhibit the ability of tumor cells and enhance the infiltration and function of CD8 + T lymphocyte cells. 2022;36:1–13. 62. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259–71. 63. Hida AI, Ohi Y. Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. Ann Oncol. 2015 Nov;26(11):2351. 64. Soumaya Mohamed Eteba MARAFMFANKM. Clinico-Epidemiological Study of Epithelial Ovarian Cancer Mansoura Experience. Http://WwwSciencepublishinggroupCom. 2018;6(4):118. 65. Fortner RT, Trewin‐Nybråten CB, Paulsen T, Langseth H. Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway. Int J Cancer. 2023 Sep 25;153(5):969–78. 66. Hao Q, Li J, Zhang Q, Xu F, Xie B, Lu H, et al. Single‐cell transcriptomes reveal heterogeneity of high‐grade serous ovarian carcinoma. Clin Transl Med. 2021 Aug 4;11(8). 67. Chen W, Liu H, Huang X, Qian L, Chen L, Zhou Y, et al. A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites. iScience. 2023 Oct;26(10):107712. 68. Cummins KA, Drapkin RI, Knarr M. Abstract B082: A pro-tumorigenic, aged microenvironment may aid in worsened disease progression in an HGSOC model. Cancer Res. 2024 Mar 4;84(5_Supplement_2):B082–B082. 69. Liu S, Liu Y, Ma J, Lv R, Wang F. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity. Medicine (Baltimore). 2023 Sep 1;102(35):e34851. 70. Oktari D, Maulani H, Auline Rusminan S, Bahar E. Tumor infiltrating lymphocytes can help to identify CD8+ tumor infiltrating lymphocytes and histopathologic subtypes of ovarian carcinoma. J Phys Conf Ser. 2019 Jul 1;1246(1):012033. 71. LAKIS S, KOTOULA V, KOLIOU GA, EFSTRATIOU I, CHRISAFI S, PAPANIKOLAOU A, et al. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. Cancer Genomics - Proteomics. 2020 Aug 28;17(5):529–41. 72. Tiper I V., Webb TJ. Targeted attack: mechanisms by which ovarian cancers suppress the immune system. Transl Cancer Res. 2016 Nov;5(S6):S1305–6. 73. Guo Q, Wang P. Tumor microenvironment landscape of epithelial ovarian carcinoma highlights EGR1-driven mechanisms of tumor invasion at single-cell resolution. Res Sq. 2022; 74. Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Donato V Di, et al. Tumor Infiltrating Lymphocytes in Ovarian Cancer. Asian Pacific J Cancer Prev. 2015 May 18;16(9):3635–8. 75. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (80- ). 2015 Apr 3;348(6230):62–8. 76. Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol. 2016 Jul;28(4):306–13. 77. Meena RK, Syed NA, Sheikh ZA, Guru FR, Mir MH, Banday SZ, et al. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov;(8). 78. Rahayu P, Syahril E, Rahmawati, Nulanda M, Dewi AS. Karakteristik Penderita Kanker Ovarium di RS Ibnu Sina Makassar. Fakumi Med J J Mhs Kedokt. 2023;3(7):359–67. 79. Sánchez-Prieto M, Sánchez-Borrego R, Lubián-López DM, Pérez-López FR. Etiopathogenesis of ovarian cancer. An inflamm-aging entity? Gynecol Oncol Reports. 2022 Aug;42:101018. 80. X.Z., Cheng., Z., Zhou., M.Y., Yang., Y.L., Cai., F., Deng., X.X. C. Prognostic factors for types I and II epithelial ovarian cancer in the elderly. Eur J Gynaecol Oncol. 2020;41(1):7. 81. Otsuka I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations. Int J Mol Sci. 2021 Apr 23;22(9):4409. 82. Curtis M, Mukherjee A, Lengyel E. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends in Cancer. 2018 Aug;4(8):517–9. 83. Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, et al. Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett. 2016 Jul;377(2):174–82.
local.eprints.dirdisk0/00/48/44/33
local.eprints.divisionS1KEDOK2024
local.eprints.id484433
local.eprints.typethesis/2Sarjana
local.eprints.urihttp://scholar.unand.ac.id/484433/
local.fakultasFakultas Kedokteran
local.identifier.nim2110311004
local.prodiS1 Kedokteran
local.thesis.levelSkripsi

Files

Collections